A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec
Status:
Recruiting
Trial end date:
2024-09-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the clinical outcomes following treatment
with nusinersen in participants with spinal muscular atrophy (SMA) who previously received
onasemnogene abeparvovec.
The secondary objectives of this study are to evaluate the safety and tolerability; and
clinical outcomes following treatment with nusinersen in participants with SMA who previously
received onasemnogene abeparvovec.